On Friday 10th June will take place the webconference “Infectious Diseases” in which Dr. Serge Morand, Ecologist at CIRAD and missioned by the IRD, will participate.
“Infectious Diseases” Conference
The conference will be online on June 10th from 8:40 to 12:30 (French time).
The event is free.
Here is the link to register: https://www.eventbrite.fr/e/billets-colloque-maladies-infectieuses-314470488697
The program of the symposium:
9:00 – 9:05 Opening Pierre SANCHEZ, Director of Publication of Pharmaceutiques and Managing Director of PR Editions
9:05 – 9:55 Round table 1
EMERGING DISEASES: A NEW HEALTH GUIDELINE IN FRANCE, EUROPE AND THE WORLD
The Covid-19 epidemic confronts us with new realities: the resurgence of emerging infectious diseases, but also the delay accumulated during the pandemic in many screening tests (particularly HIV) and the downward impact of vaccine coverage against a certain number of target pathologies. This is certainly an opportunity to prepare for the future, and to take advantage of the renewed interest of laboratories in infectious risks and of the new prospects offered by mRNA vaccines. In France, a new organization is being set up in the health field with the creation of the new ANRS, and in Europe with the HERA agency.
- Dr. Sylvie BRIAND, Director of Global Preparedness for Infectious Diseases, World Health Organization
- Pierre DELSAUX, Director General – European Health Emergency Response and Preparedness Authority (HERA)
- Dr. Eric D’ORTENZIO, Epidemiologist, Director of Strategy and Partnerships, ANRS
- Dr. Nadia KHELEF, Coordinator of the “Emerging Infectious Diseases and CBRN Threats” acceleration strategy
10h00-10h20 – Key note
WHAT LESSONS CAN BE LEARNED FROM THE CRISES (H1N1 AND COVID-19)?
Pr. Didier HOUSSIN, Chairman of the World Health Organization Emergency Committee, Former Director General of Health
10:25-11:15 – Round table 2
ANTIBIOTIC RESISTANCE: WHICH VIABLE BUSINESS MODEL?
The crisis has shown the need for treatments and vaccines to deal with emerging diseases in developed countries, a new paradigm for industrialists? What is the role of the fight against antibiotic resistance? 20 industrialists have committed to invest 1 billion euros in the Antibiotic Resistance Action Fund to make 2 to 4 new antibiotics available to patients by the end of the decade. A viable business model will have to be found for these manufacturers, who must find innovative solutions, often at low cost, and for limited uses in order not to generate new resistance…
- Dr. Jean CARLET, Honorary President of the Alliance against the development of multi-resistant bacteria, President of the 2015 Ministerial Task Force on Antibiotic Protection
- Dr. Pierre DUBOIS, Professor of Economics, Toulouse School of Economics
- Philippe LAMOUREUX, Director General of Leem
- An VAN GERVEN, Director of the Hospital Division, Pfizer France
11:20-12:15 – Round table 3
PREPARING FOR NEW RISKS: A NECESSARY MULTI-SECTORAL APPROACH
Faced with the risk of an epidemic, it is necessary to create an environment favorable to changes in the behavior of the population, and to involve the associative sector, which has the capacity to pass on information to the general public in a way that is accepted. The approach must include veterinary health in the service of human health, and in the respect of the environment, in a One health approach.
- Dr. Monique ELOIT, Director General of the World Organization for Animal Health (OIE)
- Magali HAINAUT, Director of Research and Development, Boehringer Ingelheim in France
- Dr. Serge MORAND, Health Ecologist at CNRS, Research Director at CIRAD
- Dr. Mircea T. SOFONEA, Lecturer in epidemiology and evolution of infectious diseases, University of Montpellier